Detalhe da pesquisa
1.
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Nature
; 565(7738): E4, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30532003
2.
Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Nature
; 555(7695): 274, 2018 03 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29466340
3.
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Nature
; 546(7658): 431-435, 2017 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28607484
4.
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Nature
; 550(7674): 133-136, 2017 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28953887
5.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Proc Natl Acad Sci U S A
; 105(8): 3041-6, 2008 Feb 26.
Artigo
Inglês
| MEDLINE | ID: mdl-18287029
6.
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.
Cancer Res
; 81(20): 5230-5241, 2021 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34462276
7.
A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Blood Adv
; 4(5): 906-919, 2020 03 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32150609
8.
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Clin Cancer Res
; 14(1): 230-9, 2008 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18172275
9.
Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.
Clin Cancer Res
; 24(5): 1090-1102, 2018 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29196297
10.
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Clin Cancer Res
; 24(19): 4771-4784, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29563139
11.
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
Cell Rep
; 21(10): 2796-2812, 2017 Dec 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29212027
12.
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
Cell Rep
; 21(7): 1936-1952, 2017 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29141224
13.
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.
Cell Rep
; 21(7): 1953-1967, 2017 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-29141225
14.
Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.
Mol Cancer Res
; 14(9): 767-75, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27297629
15.
Oncogenic BRAF-Mediated Melanoma Cell Invasion.
Cell Rep
; 15(9): 2012-24, 2016 05 31.
Artigo
Inglês
| MEDLINE | ID: mdl-27210749
16.
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Clin Cancer Res
; 22(7): 1592-602, 2016 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26673799
17.
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
J Clin Invest
; 126(5): 1834-56, 2016 05 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27043285
18.
Isolation of melanoma cell subpopulations using negative selection.
Methods Mol Biol
; 1102: 501-12, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24258995
19.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep
; 4(6): 1090-9, 2013 Sep 26.
Artigo
Inglês
| MEDLINE | ID: mdl-24055054
20.
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Pigment Cell Melanoma Res
; 23(6): 820-7, 2010 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-20973932